1111 GMT - U.S. President Trump's plans for 25% tariffs on pharmaceutical imports could threaten the European sector, which relies heavily on the U.S. Swiss pharma giant Roche said it is closely monitoring U.S. legislative developments and assessing any potential impact these could have on its business. The company invested over 11 billion Swiss francs ($12.18 billion) in the U.S. over the last ten years and remains committed to invest there, the company added. GSK's chief executive officer Emma Walmsley said in a media call alongside results that the company will keep a close eye on how the fast-moving tariff situation will play out in the coming weeks. The British pharma company employs around 15000 people in the U.S. and has various R&D centres and manufacturing sites across the country. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 19, 2025 06:12 ET (11:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。